KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Research & Development (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Research & Development for 8 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 17.34% year-over-year to $40.9 million, compared with a TTM value of $166.1 million through Dec 2025, down 4.87%, and an annual FY2025 reading of $166.1 million, down 4.87% over the prior year.
  • Research & Development was $40.9 million for Q4 2025 at Biocryst Pharmaceuticals, down from $44.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $162.9 million in Q4 2023 and bottomed at $37.3 million in Q1 2025.
  • Average Research & Development over 3 years is $56.0 million, with a median of $43.4 million recorded in 2025.
  • The sharpest move saw Research & Development plummeted 69.64% in 2024, then rose 15.32% in 2025.
  • Year by year, Research & Development stood at $162.9 million in 2023, then tumbled by 69.64% to $49.4 million in 2024, then dropped by 17.34% to $40.9 million in 2025.
  • Business Quant data shows Research & Development for BCRX at $40.9 million in Q4 2025, $44.6 million in Q3 2025, and $43.4 million in Q2 2025.